Mirion Technologies Inc

Aktienanalyse zu Mirion Technologies Inc (MIR)

$15.240

+0.317 (+2.08%)Zum Schluss

Loading chart…
Hoch
15.500
Eröffnung
14.810
Volumengewichteter Durchschnittskurs
15.18
Volumen
3.61M
Marktkap.
2.48B
Tief
14.800
Umsatz
54.75M
EV/EBITDA, TTM
19.03

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).

www.mirion.com

KI-Analyse of Mirion Technologies Inc (MIR)

Kaufen

Mirion Technologies Inc is a good buy right now due to its strong annual revenue growth of 11.7% over the past two years and a recent insider purchase by the CFO at $15.60, indicating confidence in the company's future. The current price is $15.15, which is below the median analyst price target of $24, suggesting significant upside potential. However, the stock has experienced a decline of 36.42% year-to-date, which poses a risk for investors.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Mirion Technologies Inc (MIR) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von 27.07.

Erwartetes KGV

Stark unterbewertet
5J-Durchschnitt P/E
27.07
Aktuelles P/E
0.00
Überbewertet
35.08
Unterbewertet
19.06

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
16.57
Aktuelles EV/EBITDA
19.03
Überbewertet
21.21
Unterbewertet
11.93

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
2.94
Aktuelles P/S
3.04
Überbewertet
4.02
Unterbewertet
1.86

Alphio-AI-Kursszenarien für MIR

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%MIR

$21.71

Szenariopreis

B

Basis

Basis · 50%MIR

$18.61

Szenariopreis

B

Bärisch

Bärisch · 25%MIR

$14.31

Szenariopreis

Whales, die MIR halten

M

Maverick Capital, Ltd.

+ HältMIR

+4.65%

3-Monats-Rendite

K

Kuwait Investment Authority

+ HältMIR

+2.17%

3-Monats-Rendite

A

Australian Foundation Investment Company Limited

+ HältMIR

-0.80%

3-Monats-Rendite

D

Davidson Kempner Capital Management LP

+ HältMIR

-8.15%

3-Monats-Rendite

MIR FAQ – beantwortet von Alphio AI

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling). It operates in the Industrials sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Mirion Technologies Inc is a good buy right now due to its strong annual revenue growth of 11.7% over the past two years and a recent insider purchase by the CFO at $15.60, indicating confidence in the company's future. The current price is $15.15, which is below the median analyst price target of $24, suggesting significant upside potential. However, the stock has experienced a decline of 36.42% year-to-date, which poses a risk for investors.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln